VX-765 is the orally available prodrug of a potent and selective competitive inhibitor of ICE/caspase-1 (VRT-043198). VX-765 is currently under clinical development for the treatment of inflammatory and autoimmune conditions,...
- Mechanism
- Curator reviewed
VX-765 is a potent and selective inhibitor of ICE/caspase-1 sub-family caspases. In preclinical trials, VX-765 was efficiently converted to VRT-043198 when administered orally to mice and inhibited LPS-induced cytokine secretion. The result was a blocking of IL-1beta and IL-18 secretion, with out much effect on the release of several other cytokines, including IL-1{alpha}, tumor necrosis factor-{alpha}, IL-6 and IL-8. There was also no demonstrable activity in cellular models of apoptosis and it did not affect the proliferation of activated primary T-cells or T-cell lines.
- Primary indication
- Investigated for use/treatment in inflammatory disorders (unspecified) and psoriasis and psoriatic disorders.Curator reviewed
- Code names
- VX-765
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Belnacasan, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account